Facebook
Linkedin
Twitter
Industries
Aerospace
Agritech
Automotive
BFSI
Biotechnology
Chemicals
Defence Technology
Energy, Power and Sustainability
Food & Beverage
Healthcare
Information Technology
MarTech
Internet Of Things (IOT)
Logistics and Supply Chain
Materials
Medical Devices
Retail
Semiconductor & Electronics
Smart Lighting
Latest News
Interviews
Insights
Guest Post
Staff Writer
Featured Article
Resource Center
Resources
Press Releases
Search
Sunday, November 3, 2024
Facebook
Linkedin
Twitter
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Privacy Policy
Password recovery
Recover your password
your email
A password will be e-mailed to you.
ReadMagazine
Industries
All
Aerospace
Agritech
Automotive
BFSI
Biotechnology
Chemicals
Defence Technology
Energy, Power and Sustainability
Food & Beverage
Healthcare
Information Technology
MarTech
Internet Of Things (IOT)
Logistics and Supply Chain
Materials
Medical Devices
Retail
Semiconductor & Electronics
Smart Lighting
Read Magazine’s Weekly News Roundup With Lockheed Martin, Ohalo, Klarna, Biogen,…
Two Six Technologies Wins $4B DTRA Contract
Telix and Subtle Medical Collaborate on AI-Powered SubtlePET for Faster Imaging
Leal Therapeutics Secures $45 Million for Innovative Neurodegenerative Treatments
Latest News
Interviews
Insights
Guest Post
Staff Writer
Featured Article
Resource Center
Resources
Press Releases
Home
Tags
ReveraGen
ReveraGen
Biotechnology
Santhera and ReveraGen Announce First Participant Dosed in FDA-funded Phase 2 Pilot Study
Globe Newswire
-
August 22, 2022
Santhera Pharmaceuticals and ReveraGen BioPharma, Inc announce that the first patient has been dosed in a Phase 2 pilot study to assess vamorolone in...
0
Fans
Like
3,912
Followers
Follow
0
Subscribers
Subscribe
Hot Topics
Read Magazine’s Weekly News Roundup With Lockheed Martin, Ohalo, Klarna, Biogen, Stepan, And More!
Two Six Technologies Wins $4B DTRA Contract
Telix and Subtle Medical Collaborate on AI-Powered SubtlePET for Faster Imaging
Load more
